Literature DB >> 20547786

Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.

A B Reid1, J R Daffy, P Stanley, K L Buising.   

Abstract

Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20547786      PMCID： PMC2934998          DOI： 10.1128/AAC.00212-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  ANTIBACTERIAL ACTIVITY OF LINCOMYCIN AND PRISTINAMYCIN: A COMPARISON WITH ERYTHROMYCIN.

Authors:  M BARBER; P M WATERWORTH
Journal:  Br Med J       Date:  1964-09-05

2.  Evolution and epidemiology of MLS resistance.

Authors:  J Duval
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

3.  Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.

Authors:  John Ng; Iain B Gosbell
Journal:  J Antimicrob Chemother       Date:  2005-04-21       Impact factor: 5.790

4.  Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  S J Dancer; A Robb; A Crawford; D Morrison
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

5.  Comparative in vitro activities of pristinamycin and other antimicrobial agents against genital pathogens.

Authors:  J C Lefevre; R Bauriaud
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

Review 6.  Linezolid: a review of safety and tolerability.

Authors:  Donald C Vinh; Ethan Rubinstein
Journal:  J Infect       Date:  2009-09       Impact factor: 6.072

7.  Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection.

Authors:  N Ruparelia; B L Atkins; J Hemingway; A R Berendt; I Byren
Journal:  J Infect       Date:  2008-08-13       Impact factor: 6.072

8.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin.

Authors:  J P Maskell; A M Sefton; J Yong; S J Chi; J D Williams
Journal:  Infection       Date:  1988       Impact factor: 3.553
  9 in total
  7 in total

1.  Monomer complexes of polyadenylic acid.

Authors:  R Jeremy; H Davies
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

2.  Design-driven, multi-use research agendas to enable applied synthetic biology for global health.

Authors:  James M Carothers
Journal:  Syst Synth Biol       Date:  2013-07-20

Review 3.  The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Authors:  Jason A Trubiano; Leon J Worth; Karin A Thursky; Monica A Slavin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 4.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics.

Authors:  Nadim Cassir; Jean-Marc Rolain; Philippe Brouqui
Journal:  Front Microbiol       Date:  2014-10-20       Impact factor: 5.640

Review 5.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

Review 6.  Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis.

Authors:  Anja R Zelmer; Renjy Nelson; Katharina Richter; Gerald J Atkins
Journal:  Bone Res       Date:  2022-08-12       Impact factor: 13.362

7.  Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection.

Authors:  Tristan Ferry; Cécile Batailler; Anne Conrad; Claire Triffault-Fillit; Frédéric Laurent; Florent Valour; Christian Chidiac
Journal:  Open Forum Infect Dis       Date:  2018-09-25       Impact factor: 3.835
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.